Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 1
2014 1
2016 1
2017 3
2018 2
2019 8
2020 9
2021 14
2022 8
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for huaihua liang
Your search for Huahua Liang retrieved no results
Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial.
Zhou S, Xiao Y, Zhou C, Zheng Z, Jiang W, Shen Q, Zhu C, Pan H, Liu C, Zeng G, Ge L, Zhang Y, Ouyang Z, Fu G, Pan G, Chen F, Huang L, Liu Q; H-REPLACE Investigators. Zhou S, et al. JAMA Netw Open. 2023 Feb 1;6(2):e2255709. doi: 10.1001/jamanetworkopen.2022.55709. JAMA Netw Open. 2023. PMID: 36763358 Free PMC article. Clinical Trial.
Clinical Features and Classification of Neuronal Intranuclear Inclusion Disease.
Tai H, Wang A, Zhang Y, Liu S, Pan Y, Li K, Zhao G, Wang M, Wu G, Niu S, Pan H, Chen B, Li W, Wang X, Dong G, Li W, Zhang Y, Guo S, Liu X, Li M, Liang H, Huang M, Chen W, Zhang Z; China NIID Collaboration Alliance. Tai H, et al. Neurol Genet. 2023 Feb 28;9(2):e200057. doi: 10.1212/NXG.0000000000200057. eCollection 2023 Apr. Neurol Genet. 2023. PMID: 37090934 Free PMC article.
A multicenter single-arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.
Shi Q, Qi X, Tang P, Fan L, Chen L, Wang S, Liang Y, Hu Y, Wang M, Ren L, Zhang G, Tan X, Yuan L, Du J, Wu X, Wang M, Che H, Lv P, Chen D, Hu J, Li Q, Zhang Y, Yang K, Zhong Y, Chen C, Zhou Z, Qian L, Zhang J, Ma M, Sun Y, Zhang Y, Jiang J. Shi Q, et al. MedComm (2020). 2023 Dec 7;4(6):e435. doi: 10.1002/mco2.435. eCollection 2023 Dec. MedComm (2020). 2023. PMID: 38077249 Free PMC article.
60 results